Add BrightSurf on Google Email

Stem cell memory CAR T cells achieve complete remissions at low doses without chemotherapy preconditioning

Researchers developed a highly homogeneous population of stem cell memory T cells that exhibit superior expansion and persistence, enabling complete responses at low doses. The study showed a favorable tolerability profile and demonstrated the separation between beneficial effects and toxic consequences.

SourceLeibniz Institute for Immunotherapy·JournalCell·TypeRandomized controlled/clinical trial·DateApr 30, 2026

Cellular neighborhoods inside tumors may predict which patients with melanoma benefit from combination immunotherapy

Researchers found that tumor genetics alone did not explain which patients responded to combination therapy, but rather the tumor's immune environment. Patients with active networks of cancer-killing T cells were more likely to benefit from treatment, while those with dense clusters of plasma cells were less likely.

Understanding the diverse chemokine signals in tumor microenvironment for advanced immunotherapy

Chemokines regulate immune cell infiltration and local immunity in tumors, and targeting their receptor axis has emerged as a promising therapeutic target in cancer immunotherapy. Chemokine-modulating strategies combining with other immunotherapies have demonstrated considerable synergistic potential.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateApr 20, 2026

First-in-class dual HIF inhibitors eliminate breast, colorectal, melanoma, and prostate tumors in mice when combined with immunotherapy

Researchers developed first-in-class dual HIF inhibitors that, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice. The drugs target HIF-1/2 transcription factors, which are key regulators of cancer progression.

SourceRockefeller University Press·JournalJournal of Experimental Medicine·TypeExperimental study·DateApr 2, 2026

Simple tumor biomarker test predicts which stomach cancer patients will respond to immunotherapy

Researchers have discovered a tumor biomarker that can predict which gastric cancer patients will benefit from immunotherapy before surgery. The biomarker, tsMHC-II expression, showed strong correlation with treatment response and was easily assessable using standard immunohistochemistry techniques.

SourceScience China Press·JournalScience Bulletin·TypeRandomized controlled/clinical trial·DateMar 27, 2026

Triple combination therapy before surgery helps boost immunity against aggressive soft tissue sarcomas

Researchers found that combining targeted radiation therapy with BO-112 and anti-PD-1 therapy before surgery activated the immune system to fight cancer. This approach reshaped the tumor microenvironment to support T-cell activity, resulting in fewer cancer cells and a more effective anti-tumor response.

New study finds common blood pressure drug boosts cancer treatment

A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.

SourceDartmouth Health·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateMar 25, 2026

ECOG-ACRIN completes enrollment for 600-patient clinical trial focused on frontline therapy for advanced melanoma

The ECOG-ACRIN Cancer Research Group has completed enrollment of 600 patients in the phase 2/3 trial EA6141, evaluating dual checkpoint blockade with nivolumab and ipilimumab plus sargramostim for unresectable stage 3 or 4 melanoma. The trial aims to assess overall survival, progression-free survival, and treatment tolerability.

Immunotherapy plus chemotherapy before surgery shows promise for pancreatic cancer

A new UCLA study found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. The combination treatment helped patients live long enough to reach surgery, shrank tumors, and produced encouraging survival outcomes.

The Frontiers of Knowledge Award goes to Carl June and Michel Sadelain for revolutionizing cancer treatment using immunotherapy based on the patient’s own genetically modified cells

Researchers have developed a breakthrough technique to transform a patient's own T cells into soldiers trained to recognize and kill cancer cells, benefiting tens of thousands of individuals with blood cancers. The approach is now being explored for solid tumors and other diseases.

Could these two genes make T cells unstoppable?

Researchers at Salk Institute uncover two transcription factors, ZSCAN20 and JDP2, that determine T cell fate. Turning off these genes reverses T cell exhaustion and restores their ability to kill tumors without losing immune memory. The study challenges the long-standing belief of inevitable immune exhaustion.

SourceSalk Institute·JournalNature·DateFeb 4, 2026

Immunotherapy reduces plaque in arteries of mice

A novel antibody-based therapy has been shown to reduce plaque in the arteries of mice, eliminating harmful immune cells that drive inflammation and unstable plaque formation. This immunotherapy could complement traditional methods and help patients with advanced coronary artery disease.

SourceWashU Medicine·JournalScience·DateJan 29, 2026

Mount Sinai study finds antibody-producing immune cells can help shape cancer immunotherapy

A Mount Sinai study found that antibody-producing immune cells called IgG1 plasma cells help patients respond to PD-1 immune checkpoint inhibitors, which have transformed cancer care. The researchers identified IgG1 plasma cells as a critical factor in determining clinical outcomes.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNature Medicine·TypeMeta-analysis·DateJan 27, 2026

How do nature and nurture shape our immune cells?

Researchers at Salk Institute debut an epigenetic catalog that shows genetic inheritance and life experiences have distinct effects on various types of immune cells, shedding light on individual differences in immune responses and potential new personalized therapeutics.

SourceSalk Institute·JournalNature Genetics·DateJan 27, 2026

Chinese Medical Journal article review: cGAS‑STING pathway emerges as cornerstone for next‑generation immunotherapies

The cGAS-STING pathway plays a crucial role in detecting cellular DNA, triggering type I interferons and cytokines, and modulating immune responses. Its therapeutic potential is being explored in cancer and various diseases, with promising preclinical evidence suggesting its potential as a target for next-generation immunotherapies.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·DateJan 26, 2026

Hope for smarter lung cancer care

A study from Flinders University found that patients with progressive disease, which describes the way cancer grows, have varying survival rates depending on whether their existing tumours re-grow or new ones appear. Understanding this progression can help doctors make better decisions about future treatment strategies.

SourceFlinders University·JournalCancer Letters·TypeMeta-analysis·DateJan 21, 2026

“Recipe book” for reprogramming immune cells

Researchers have created a library of over 400 immune-related factors to reprogram rare immune cell populations. This technique allows for the systematic discovery of 'recipes' for specific immune cells, offering hope for unresponsive patients and advancing immunotherapy.

SourceLund University·JournalCell Systems·TypeExperimental study·DateJan 14, 2026